Premium
THE NOVEL BISPECIFIC CD47‐CD19 ANTIBODY TG‐1801 POTENTIATES THE ACTIVITY OF UBLITUXIMAB‐UMBRALISIB (U2) DRUG COMBINATION IN PRECLINICAL MODELS OF B‐NHL
Author(s) -
Normant E.,
Ribeiro M.L.,
Reyes D.,
Miskin H.P.,
Sportelli P.,
Weiss M.S.,
Bosch F.,
Roue G.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.133_2630
Subject(s) - cd47 , antibody dependent cell mediated cytotoxicity , cancer research , medicine , cd19 , cd20 , antibody , b cell , immunology , pharmacology , monoclonal antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom